Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVITA Medical, Inc.RCEL · Entity 5905 | CFO | June 12, 2026 | August 24, 2026 |
| SOLENO THERAPEUTICS INCCAPN · Entity 46432 | Director | April 19, 2017 | April 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVITA Medical, Inc.
Report date June 12, 2026 · Filed August 24, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 152,927 |
Reported balance
After 2026-06-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-06-12 · Purchase · Acquired 2,000 · Balance 152,927 F1: The original Form 4, filed on June 12, 2026, inadvertently used transaction code 'A' instead of transaction code 'P'. This amendment corrects the transaction code. F2: Includes unvested RSUs |
Filing footnotes · ownership attribution and instrument terms
F1: The original Form 4, filed on June 12, 2026, inadvertently used transaction code 'A' instead of transaction code 'P'. This amendment corrects the transaction code.
F2: Includes unvested RSUs
SOLENO THERAPEUTICS INC
Report date April 19, 2017 · Filed April 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2027-04-19 | Direct | 354,945 |
Reported balance
After 2017-04-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-19 · Grant · Acquired 354,945 · Balance 354,945 F1: One fourth (1/4) of the shares subject to the Option shall vest immediately on the Vesting Commencement Date (which is April 19, 2017), and one forty-eighth (1/48) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to Participant continuing to be a Service Provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth (1/4) of the shares subject to the Option shall vest immediately on the Vesting Commencement Date (which is April 19, 2017), and one forty-eighth (1/48) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to Participant continuing to be a Service Provider through each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OPIANT PHARMACEUTICALS, INC.
Report date March 02, 2023 · Filed March 03, 2023
Section 16 reporting ended · disclosed 2023-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-03-02 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-03-02 · Disposition to issuer · Disposed 22,512 · Balance 11,736 F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Row 2 · 2023-03-02 · Disposition to issuer · Disposed 11,736 · Balance 0 F2: Disposed of pursuant to the Merger Agreement, in exchange for the Merger Consideration. The number of shares disposed of reflects 11,736 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement. Row 3 · 2023-03-02 · Grant · Acquired 2,000 · Balance 2,000 F3: 2,000 shares are represented by performance stock units ("PSUs"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer. Row 4 · 2023-03-02 · Disposition to issuer · Disposed 2,000 · Balance 0 F4: Disposed of pursuant the Merger Agreement, in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.61 · Expires 2029-01-02 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-02 · Disposition to issuer · Disposed 33,000 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.15 · Expires 2031-01-26 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-03-02 · Disposition to issuer · Disposed 10,750 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2030-01-07 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-02 · Disposition to issuer · Disposed 8,250 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
F2: Disposed of pursuant to the Merger Agreement, in exchange for the Merger Consideration. The number of shares disposed of reflects 11,736 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
F3: 2,000 shares are represented by performance stock units ("PSUs"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer.
F4: Disposed of pursuant the Merger Agreement, in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement.
F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2023 Filed Jan 9, 2023 22:16 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 415 | $20.20 | $8,383.00 |
DisclosureSEC source: 0001385508-23-000024 · wf-form4_167330254788792.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,789 F1 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 22:03 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 1,600 | $20.20 | $32,320.00 |
DisclosureSEC source: 0001385508-23-000011 · wf-form4_167295619781599.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,204 F1 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 20:06 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 779 | $11.10 | $8,646.90 |
DisclosureSEC source: 0001385508-22-000112 · wf-form4_165791560118442.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,804 F1 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of performance stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.82 to $11.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 20:04 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-22-000102 · wf-form4_165653307620662.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,583 F1 · shares: Represents the acquisition of shares upon the determination on June 27, 2020 by the Compensation and Human Capital Committee of the Board of Directors of the Issuer that the performance conditions were met with respect to a portion of the performance stock units granted to the Reporting Person on January 4, 2022. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:39 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 432 | $30.60 | $13,219.20 |
DisclosureSEC source: 0001385508-22-000022 · wf-form4_164202352936884.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,583 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $29.03 to $30.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:21 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-22-000012 · wf-form4_164141760647083.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,015 F1 · kind: 12,000 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-third of the RSUs vest on the anniversary dates of January 4, 2023, January 4, 2024 and January 4, 2025, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 20:02 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 21 | $19.05 | $400.05 |
DisclosureSEC source: 0001385508-21-000132 · wf-form4_163173616376901.xml · nonDerivative · entry 2 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,015 Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 20:02 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 179 | $19.13 | $3,424.27 |
DisclosureSEC source: 0001385508-21-000132 · wf-form4_163173616376901.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,994 Read SEC document |
| August 16, 2021 Filed Aug 16, 2021 20:47 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 600 | $15.38 | $9,228.00 |
DisclosureSEC source: 0001385508-21-000111 · wf-form4_162914682979973.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,815 Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 21:20 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantStock Option (right to buy) · Derivative | 10,750 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001385508-21-000017 · wf-form4_161178239296219.xml · derivative · entry 3 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,750 Underlying: Common Stock · 10,750 shares Expires 2031-01-26 F3 · derivative.exercise_date: On January 26, 2021, the reporting person was granted an option to purchase 10,750 shares of common stock. The option vests as follows: 1/48 of the options become exercisable on the first monthly anniversary of January 26, 2021, the vesting commencement date, and 1/48 of the options become exercisable on such date every month thereafter through the fourth year anniversary of the vesting commencement date. Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 21:20 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 5,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-21-000017 · wf-form4_161178239296219.xml · nonDerivative · entry 2 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,215 F2 · kind: 5,400 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-fourth of the RSUs vest on the anniversary dates of January 26, 2022, January 26, 2023, January 26, 2024 and January 26, 2025, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 21:20 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-21-000017 · wf-form4_161178239296219.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,815 F1 · kind: 2,450 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. 100% of the RSUs vest on the anniversary date of January 26, 2022, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 11, 2020 Filed Jun 11, 2020 20:06 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 1,000 | $8.74 | $8,740.00 |
DisclosureSEC source: 0001385508-20-000067 · wf-form4_159190596595509.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,365 Read SEC document |
| May 26, 2020 Filed May 26, 2020 20:25 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 1,000 | $11.00 | $11,000.00 |
DisclosureSEC source: 0001385508-20-000061 · wf-form4_159052473424099.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,365 Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 21:14 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock · Derivative | 8,250 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0001385508-20-000017 · wf-form4_157860445295848.xml · derivative · entry 2 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 Underlying: Common Stock · 8,250 shares Expires 2030-01-07 F2 · derivative.exercise_date: On January 7, 2020, the reporting person was granted an option to purchase 8,250 shares of common stock. The option vests as follows: 1/48 of the options become exercisable on the first monthly anniversary of the vesting commencement date, and 1/48 of the options become exercisable on such date every month thereafter through the fourth year anniversary of the Grant Date. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 21:14 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 4,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-20-000017 · wf-form4_157860445295848.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,365 F1 · kind: 4,150 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-fourth of the RSUs vest on the anniversary dates of January 7, 2021, January 7, 2022, January 7, 2023 and January 7, 2024, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| November 26, 2019 Filed Nov 26, 2019 21:01 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 100 | $13.22 | $1,322.00 |
DisclosureSEC source: 0001385508-19-000121 · wf-form4_157480207097959.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,215 Read SEC document |
| November 15, 2019 Filed Nov 15, 2019 21:02 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 100 | $15.00 | $1,500.00 |
DisclosureSEC source: 0001385508-19-000117 · wf-form4_157385172311589.xml · nonDerivative · entry 2 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,115 Read SEC document |
| November 15, 2019 Filed Nov 15, 2019 21:02 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 1,000 | $14.91 | $14,910.00 |
DisclosureSEC source: 0001385508-19-000117 · wf-form4_157385172311589.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,015 Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 20:05 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 1,000 | $15.20 | $15,200.00 |
DisclosureSEC source: 0001385508-19-000088 · wf-form4_156589951599581.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,015 Read SEC document |
| August 13, 2019 Filed Aug 13, 2019 20:02 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 1,000 | $15.46 | $15,460.00 |
DisclosureSEC source: 0001385508-19-000086 · wf-form4_156572654992515.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,015 F1 · price: This transaction was executed in multiple trades at prices ranging from $15.40 to $15.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 22:18 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantStock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $13.61 | $0.00 |
DisclosureSEC source: 0001385508-19-000006 · wf-form4_154664028137802.xml · derivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: On January 3, 2019, the reporting person was granted an option to purchase 33,000 shares of common stock. The option vests as follows: 1/48 of the options become exercisable on the first monthly anniversary of the vesting commencement date, and 1/48 of the options become exercisable on such date every month thereafter through the fourth anniversary of the Grant Date. Read SEC document |
| August 14, 2018 Filed Aug 14, 2018 20:04 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 1,000 | $15.39 | $15,390.00 |
DisclosureSEC source: 0001385508-18-000071 · wf-form4_153427698317213.xml · nonDerivative · entry 2 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,015 Read SEC document |
| August 14, 2018 Filed Aug 14, 2018 20:04 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 15 | $16.40 | $246.00 |
DisclosureSEC source: 0001385508-18-000071 · wf-form4_153427698317213.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,015 Read SEC document |
| May 16, 2018 Filed May 16, 2018 20:01 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 2,000 | $16.95 | $33,900.00 |
DisclosureSEC source: 0001385508-18-000045 · wf-form4_152650089733388.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| May 11, 2018 Filed May 14, 2018 20:01 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 3,000 | $18.85 | $56,550.00 |
DisclosureSEC source: 0001385508-18-000041 · wf-form4_152632805284065.xml · nonDerivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 23:34 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $24.84 | $0.00 |
DisclosureSEC source: 0001385508-18-000004 · wf-form4_151545445086053.xml · derivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2028-01-03 F1 · derivative.exercise_date: On January 4, 2018, the reporting person was granted an option to purchase 13,200 shares of common stock. The option vests as follows: Twenty-five percent (25%) of the shares of common stock underlying the option shall vest on the one-year anniversary of the date of grant, and 2.083% of the shares of common stock underlying the option shall vest monthly thereafter, becoming fully vested on the four-year anniversary of the date of grant. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 23:00 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $36.00 | $0.00 |
DisclosureSEC source: 0001144204-17-048089 · v475189_4.xml · derivative · entry 1 O'Toole David D · CIK 0001491140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-09-11 F1 · derivative.exercise_date: On September 12, 2017, the reporting person was granted an option to purchase 150,000 shares of common stock. The option vests as follows: Twenty-five percent (25%) of the shares of common stock underlying the option shall vest on the one-year anniversary of the date of grant, and 2.083% of the shares of common stock underlying the option shall vest monthly thereafter, becoming fully vested on the four-year anniversary of the date of grant. F1 · balance_after: On September 12, 2017, the reporting person was granted an option to purchase 150,000 shares of common stock. The option vests as follows: Twenty-five percent (25%) of the shares of common stock underlying the option shall vest on the one-year anniversary of the date of grant, and 2.083% of the shares of common stock underlying the option shall vest monthly thereafter, becoming fully vested on the four-year anniversary of the date of grant. Read SEC document |
| April 19, 2017 Filed Apr 24, 2017 10:17 UTC | SOLENO THERAPEUTICS INC CAPN · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 354,945 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0000899243-17-010763 · doc4.xml · derivative · entry 1 O'Toole David D · CIK 0001491140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,945 Underlying: Common Stock · 354,945 shares Expires 2027-04-19 F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the Option shall vest immediately on the Vesting Commencement Date (which is April 19, 2017), and one forty-eighth (1/48) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to Participant continuing to be a Service Provider through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.